 |
| 셀트리온 본사 전경. (사진=셀트리온) |
[Alpha Biz=(Chicago) Reporter Paul Lee] NH Investment & Securities analyzed that Celltrion's performance will gradually improve in the second half of the year
NH Investment & Securities analyzed on the 4th that its performance will gradually improve in the second half of the year as Celltrion's cost ratio falls. Next year's operating profit is expected to double from this year. Investment opinion 'buy' and target stock price remained at 220,000 won.
"Celltrion's expected sales this year rose 56% year-on-year to KRW 392.8 billion and operating profit fell 8% year-on-year to KRW 600.1 billion. "The cost ratio of the first quarter will be high at 62% due to the absolutely high proportion of expensive healthcare inventory, but as the quarter goes by, the cost ratio of the fourth quarter will fall to 39%," NH Investment & Securities said.
"The sales price of ZYMFENTRA (Ramshima SC) is two to three times higher than that of Europe's Ramshima SC, which has a very high cost ratio," said NH Investment & Securities. "The company's total return on sales will improve significantly from the time when Ramshima SC sales take effect."
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
